title: Cutaneous side effects of vemurafenib: a case report and discussion.
abstract: In 2011, the FDA approved the drug vemurafenib, a potent kinase inhibitor with specificity for the BRAF V600E mutation, for the treatment of metastatic melanoma. While this drug is otherwise well-tolerated, many patients develop cutaneous toxicities. This report demonstrates multiple cutaneous toxicities in a patient while undergoing treatment with vemurafenib.
authors.affiliation: Department of Pathology, University of Virginia, USA. sms7d@virginia.edu
authors.forename: Sofia M
authors.initials: SM
authors.lastname: Shea
authors.forename: Katherine
authors.initials: K
authors.lastname: Boyd
authors.forename: James
authors.initials: J
authors.lastname: Patterson
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D004379:Duodenal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000601:surgery; D005260:Female; D006225:Hand; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007866:Leg; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D012086:Reoperation; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib; D014860:Warts / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib